|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Notice to Readers Ansamycin LM427Since October 1983, CDC's Division of Tuberculosis Control, Center for Prevention Services, has supplied the experimental drug, ansamycin LM427, under a "compassionate" investigational new drug permit to physicians treating patients with serious mycobacterial disease unresponsive to conventional therapy. Beginning Monday, February 18, 1985, physicians requesting the drug for new patients should contact the CDC Drug Service at (404) 329-3670 during normal working hours. Ansamycin LM427 is not released at night or during weekends. The Division of Tuberculosis Control ((404) 329-2530) will continue to provide medical consultation on the treatment of mycobacterial diseases. Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 08/05/98 |
|||||||||
This page last reviewed 5/2/01
|